SUFU germline pathogenic variants cause a Gorlin-syndrome–like predisposition with much h...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-SUFU-GERMLINE-MEDULLOBLASTOMA |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-05-18 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-GBM |
| Sources | SRC-NCCN-CNS-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-SUFU-GERMLINE |
|---|---|
| Variante | SUFU pathogène génomique (comme le SNCB, le médulloblastome-prédominant) |
| Maladie | DIS-GBM |
| Niveau ESCAT | IIA |
| Combinaisons recommandées | brain MRI q4mo to age 3, q6mo to age 5, annual to age 8 — earlier and denser than PTCH1 cadence, dermatology surveillance q6-12mo from puberty, neurosurgery + COG-based protocols for medulloblastoma (avoid EBRT where alternatives available), do NOT default to vismodegib / sonidegib for SUFU-driven SHH-MB — downstream-of-SMO position renders SMO inhibition ineffective; consider GLI-pathway investigational agents in trial setting |
| Contre-indiqué en monothérapie | vismodegib / sonidegib (SMO inhibitors) — limited efficacy in SUFU-mutant medulloblastoma; not a substitute for chemotherapy / radiation |
| Résumé des faits | SUFU germline pathogenic variants cause a Gorlin-syndrome–like predisposition with much higher medulloblastoma risk than PTCH1 (~30% lifetime vs ~5% in PTCH1), and lower BCC burden. SUFU-driven medulloblastomas cluster in the SHH-activated molecular subgroup (infant/young-child onset, desmoplastic / MBEN histology in many cases). Confirmed-carrier surveillance protocol (per Foulkes et al. 2017 / AACR Pediatric Predisposition Working Group): brain MRI q4mo from diagnosis through age 3, q6mo from age 3-5, annually to age 8 — denser-than-PTCH1 cadence reflects higher MB risk. Dermatology surveillance for BCC q6-12mo from puberty. Avoid craniospinal external-beam radiation when alternatives exist (second-malignancy risk in carriers). Hedgehog-pathway inhibitors (vismodegib, sonidegib) have limited activity in SUFU-mutant SHH-MB — downstream-of-SMO position renders SMO inhibitors ineffective; this is a critical distinction from PTCH1-driven disease. ESCAT IIA. |
Notes
STUB — Wave A+B germline expansion. Linked Indication: none (no SUFU-/Gorlin- specific Indication exists yet). Two-Clinical-Co-Lead signoff queued. Disease anchor uses DIS-GBM as closest CNS-tumor anchor; medulloblastoma lacks a Disease entity. The PTCH1-vs-SUFU distinction matters clinically: higher MB risk + tighter surveillance cadence + SMO-inhibitor resistance. Penetrance estimates remain unstable due to small published cohorts.
Utilisé par
No reverse references found in the YAML corpus.